Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H | WB, ICC | M | Purified | Monoclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | MAB10754 |
| Replaces | 04-573; 04-574 |
| Description | Anti-Caspase-8 (active form p18 subunit) Antibody, clone 2B12.1 |
| Alternate Names |
|
| Background Information | Caspase-8 (MACH/FLICE/Mch5) is a member of a family of cysteine-requiring aspartate proteases that participate in the intracellular signaling cascade leading to apoptosis, or programmed cell death. Caspase-8 is recruited to death-inducing signaling complex (DISC), CD95 (Fas/APO-1) and tumor necrosis factor receptor 1 (TNFR1) and is subsequently activated by proteolytic cleavage into two residues, p10 and p18. Active caspase-8 or the p18 subunit, is the first in the caspase signaling cascade, and it signals downstream caspases to eventually induce apoptosis. |
| Product Information | |
|---|---|
| Format | Purified |
| Control |
|
| Presentation | Purified mouse monoclonal IgMκ in buffer containing PBS with 0.05% sodium azide. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Detect Caspase-8 (active form p18 subunit) using this Anti-Caspase-8 (active form p18 subunit) Antibody, clone 2B12.1 validated for use in WB & IC. |
| Key Applications |
|
| Application Notes | Immunocytochemistry Analysis: A 1:500 dilution from a previous lot detected active Caspase-8 (p18 subunit) in etoposide-treated HeLa cells. |
| Biological Information | |
|---|---|
| Immunogen | KLH-conjugated linear peptide corresponding to the active form of human Caspase-8. |
| Clone | 2B12.1 |
| Concentration | Please refer to the Certificate of Analysis for the lot-specific concentration. |
| Host | Mouse |
| Specificity | This antibody recognizes the active form (p18 subunit) of Caspase-8. |
| Isotype | IgMκ |
| Species Reactivity |
|
| Antibody Type | Monoclonal Antibody |
| Entrez Gene Number |
|
| Entrez Gene Summary | This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes composed of a prodomain, a large protease subunit, and a small protease subunit. Activation of caspases requires proteolytic processing at conserved internal aspartic residues to generate a heterodimeric enzyme consisting of the large and small subunits. This protein is involved in the programmed cell death induced by Fas and various apoptotic stimuli. The N-terminal FADD-like death effector domain of this protein suggests that it may interact with Fas-interacting protein FADD. This protein was detected in the insoluble fraction of the affected brain region from Huntington disease patients but not in those from normal controls, which implicated the role in neurodegenerative diseases. Many alternatively spliced transcript variants encoding different isoforms have been described, although not all variants have had their full-length sequences determined. [provided by RefSeq]. |
| Gene Symbol |
|
| Purification Method | Ion Exchange |
| UniProt Number |
|
| UniProt Summary | FUNCTION: Most upstream protease of the activation cascade of caspases responsible for the TNFRSF6/FAS mediated and TNFRSF1A induced cell death. Binding to the adapter molecule FADD recruits it to either receptor. The resulting aggregate called death- inducing signaling complex (DISC) performs CASP8 proteolytic activation. The active dimeric enzyme is then liberated from the DISC and free to activate downstream apoptotic proteases. Proteolytic fragments of the N-terminal propeptide (termed CAP3, CAP5 and CAP6) are likely retained in the DISC. Cleaves and activates CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10. May participate in the GZMB apoptotic pathways. Cleaves ADPRT. Hydrolyzes the small-molecule substrate, AC-Asp-Glu-Val-Asp- -AMC. Likely target for the cowpox virus CRMA death inhibitory protein. Isoforms 5, 6, 7 and 8 lack the catalytic site and may interfere with the pro-apoptotic activity of the complex. SIZE: 479 amino acids; 55391 Da SUBUNIT: Heterotetramer that consists of two anti-parallel arranged heterodimers, each one formed by a 18 kDa (p18) and a 10 kDa (p10) subunit. Interacts with FADD, CFLAR and PEA15. Isoform 9 interacts at the endoplasmic reticulum with a complex containing BCAP31, BAP29, BCL2 and/or BCL2L1. SUBCELLULAR LOCATION: Cytoplasm. TISSUE SPECIFICITY: Isoforms 1, 5 and 7 are expressed in a wide variety of tissues. Highest expression in peripheral blood leukocytes, spleen, thymus, and liver. Barely detectable in brain, testis, and skeletal muscle.DOMAIN:SwissProt: Q14790 Isoform 9 contains a N-terminal extension that is required for interaction with the BCAP31 complex. PTM: Generation of the subunits requires association with the death-inducing signaling complex (DISC), whereas additional processing is likely due to the autocatalytic activity of the activated protease. GZMB and CASP10 can be involved in these processing events. & Phosphorylated upon DNA damage, probably by ATM or ATR. DISEASE: Defects in CASP8 are the cause of caspase-8 deficiency (CASP8D) [MIM:607271]. CASP8D is a disorder resembling autoimmune lymphoproliferative syndrome (ALPS). It is characterized by lymphadenopathy, splenomegaly, and defective CD95-induced apoptosis of peripheral blood lymphocytes (PBLs). It leads to defects in activation of T-lymphocytes, B-lymphocytes, and natural killer cells leading to immunodeficiency characterized by recurrent sinopulmonary and herpes simplex virus infections and poor responses to immunization. SIMILARITY: Belongs to the peptidase C14 family. & Contains 2 DED (death effector) domains. |
| Molecular Weight | ~18 kDa observed |
| Product Usage Statements | |
|---|---|
| Quality Assurance | Evaluated by Western Blot in camptothecin-treated and untreated Jurkat lysates. Western Blot Analysis: 2 µg/mL of this antibody detected the active form of Caspase-8 (p18 subunit) in 10 µg of camptothecin-treated Jurkat lysates. Untreated jurkat lysate exhibited no detection of active Caspase-8. |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable for 1 year at 2-8°C from date of receipt. |
| Packaging Information | |
|---|---|
| Material Size | 200 µg |